Tetracomb

Tetracomb is a topical combination product containing a corticosteroid (triamcinolone), two antibacterial agents (neomycin and gramicidin), and an antifungal agent (nystatin). It is indicated for the treatment of inflammatory skin conditions that are complicated, or likely to be complicated, by superficial bacterial and/or candidal (yeast) infection.

Established / commonly accepted uses

• Infected or infection-prone eczema (atopic, contact, nummular, seborrhoeic, or infantile eczema) with secondary bacterial or candidal infection
• Infected intertrigo (skin-fold rash), including candidal intertrigo
• Diaper (napkin) dermatitis complicated by secondary bacterial or candidal infection
• Anogenital pruritus associated with mixed bacterial/fungal infection
• Otitis externa (external ear canal infection), when the eardrum is intact

Adjunct / combination-dependent use

• Psoriasis or neurodermatitis when these are complicated by secondary bacterial or candidal superinfection — used as an adjunct to standard therapy, not as monotherapy for the underlying disease

Tetracomb is intended for short-term use in mixed inflammatory-infective skin conditions and is not appropriate for skin disorders without evidence or strong suspicion of secondary bacterial or fungal infection, since unnecessary use of the antibacterial/antifungal and corticosteroid components increases the risk of resistance, sensitization, and skin atrophy.

Each gram of Triamcinolone + Neomycin + Nystatin + Gramicidin cream/ointment typically contains:

• Triamcinolone acetonide BP - 1 mg
• Neomycin sulphate BP (equivalent to neomycin) - 2.5 mg
• Nystatin BP - 100,000 IU
• Gramicidin BP - 0.25 mg

Strengths and exact excipients may vary slightly by manufacturer; refer to the specific product label for the marketed formulation.

Tetracomb is a fixed-dose combination topical preparation formulated as a cream or ointment for dermatological and, in some formulations, otic (ear) use. It combines a mid-to-high potency synthetic corticosteroid (triamcinolone acetonide) with two antibacterial agents active mainly against gram-positive and some gram-negative organisms (neomycin and gramicidin) and an antifungal agent specific for Candida species (nystatin).

This combination allows simultaneous control of inflammation, itching, and mixed bacterial/fungal infection in a single topical product, which is useful in conditions such as infected eczema, intertrigo, and infected diaper dermatitis where more than one pathogenic process is usually present.

Tetracomb belongs to the therapeutic class of topical corticosteroid combined with antibacterial and antifungal agents, used for dermatological anti-inflammatory and anti-infective therapy.

Triamcinolone + Neomycin + Nystatin + Gramicidin combines four active components with complementary mechanisms:

• Triamcinolone acetonide is a synthetic corticosteroid that binds intracellular glucocorticoid receptors, reducing the synthesis and release of inflammatory mediators. This produces anti-inflammatory, antipruritic, and vasoconstrictive effects on the skin.
• Neomycin sulphate is an aminoglycoside antibacterial that inhibits bacterial protein synthesis by binding the 30S ribosomal subunit, giving bactericidal activity mainly against gram-negative organisms and some gram-positive cocci.
• Gramicidin is a polypeptide antibiotic that disrupts bacterial cell membrane function, active mainly against gram-positive organisms; it complements neomycin's spectrum.
• Nystatin is a polyene antifungal that binds ergosterol in the fungal cell membrane, forming pores that increase membrane permeability and cause fungal cell death. It is active against Candida albicans and other Candida species but has negligible systemic absorption from intact or broken skin.

Topical application after skin application results in minimal systemic absorption under normal use, although absorption of the corticosteroid and neomycin components may increase with prolonged use, application to large body surface areas, use on broken or denuded skin, or use under occlusive dressings (including diapers).

Apply Tetracomb topically to clean, dry skin. Wash hands before and after application (unless the hands are the area being treated). Use only a thin layer sufficient to cover the affected area; avoid excessive application. Do not use on the face for prolonged periods, and avoid application near the eyes. Do not cover the treated area with an airtight or occlusive dressing unless directed by a physician, as this increases systemic absorption. If used in the ear, do not use if the eardrum is perforated.

Tetracomb is applied topically, and clinically significant systemic drug interactions are uncommon with normal use. However, the following should be considered:

• Other topical or systemic corticosteroids: Concurrent use with other corticosteroid-containing products (topical, inhaled, or oral) may increase the total corticosteroid load and the risk of systemic and cutaneous corticosteroid adverse effects, especially with extensive or prolonged use.
• Other topical or systemic aminoglycosides (e.g., gentamicin, tobramycin) or ototoxic/nephrotoxic drugs: Concomitant use may theoretically add to the risk of ototoxicity or nephrotoxicity if significant systemic absorption of neomycin occurs (e.g., with use over large denuded areas or under occlusion).
• Other topical antifungal or antibacterial products applied to the same site: May cause additive local irritation; avoid unnecessary co-application to the same area without medical advice.

Inform your physician or pharmacist about all other topical and systemic medicines you are using before starting Tetracomb.

Most side effects of Tetracomb are local and related to the site of application. Systemic side effects are uncommon with correct short-term use but risk increases with prolonged use, large treatment areas, or use under occlusion.

Common

• Burning, stinging, or itching at the application site
• Dryness or mild irritation of the skin

Less common

• Contact sensitization/allergic contact dermatitis (particularly to neomycin)
• Skin atrophy, striae, telangiectasia, or hypopigmentation with prolonged corticosteroid use
• Perioral dermatitis, acneiform eruptions, or worsening of rosacea with prolonged facial use
• Secondary infection due to suppression of local immune response (masked infection) with prolonged use

Rare/serious

• Signs of hypersensitivity reaction: rash, hives, swelling of the face/lips/tongue/throat, difficulty breathing (seek immediate medical attention)
• Systemic corticosteroid effects (e.g., adrenal suppression) or ototoxicity/nephrotoxicity from neomycin absorption, mainly with extensive, prolonged, or occlusive use, especially in infants and young children

Pregnancy: There are limited controlled data on the use of Tetracomb in pregnant women. Topical corticosteroids and aminoglycosides can be absorbed systemically, particularly with use over large areas, on broken skin, or under occlusion. Tetracomb should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use the smallest effective amount for the shortest duration necessary, and consult a physician before use.

Lactation: It is not known whether topically applied components of Tetracomb are excreted in clinically significant amounts in human breast milk. Caution is advised if used by breastfeeding women, particularly avoiding application to the breast/nipple area before nursing. Consult a physician before use while breastfeeding.

Use Tetracomb only on the skin (or ear, if the eardrum is intact) as directed by a physician, and only for as long as necessary; avoid prolonged or repeated courses of treatment.

• Avoid application to large areas of the body, broken or denuded skin, or under occlusive dressings (including tight diapers), as this increases systemic absorption of the corticosteroid and neomycin, raising the risk of systemic corticosteroid effects, skin atrophy, and neomycin-related ototoxicity/nephrotoxicity.
• Prolonged use, especially of the neomycin component, increases the risk of contact sensitization; discontinue if sensitization or worsening irritation develops.
• Avoid use on the face for prolonged periods due to the risk of perioral dermatitis, acneiform eruptions, and skin atrophy.
• Not for ophthalmic use; avoid contact with the eyes.
• Do not use in the ear canal if the eardrum is perforated.
• Use with caution in infants and young children, who have a higher skin surface-area-to-body-weight ratio and are therefore more susceptible to systemic absorption (see Use in special populations).
• If signs of infection persist or worsen, or a new infection develops during treatment, discontinue and consult a physician, since topical corticosteroids can mask signs of infection.

Take Tetracomb exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Topical overdose with Tetracomb is unlikely with correct use but may occur with excessive or prolonged application, or accidental ingestion. Symptoms of excessive topical use may include increased local irritation, skin atrophy, or signs of systemic corticosteroid or aminoglycoside absorption (e.g., unusual fatigue, hearing changes). Accidental oral ingestion may cause gastrointestinal upset or other systemic effects.

If overdose or accidental ingestion is suspected, seek immediate medical attention or contact a poison control center right away. Do not attempt home treatment beyond removing residual product from the skin.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep the container tightly closed. Keep out of reach of children.

Pediatric use

Tetracomb should be used in infants and children only under medical supervision and generally not in infants under 1 year of age, due to a higher risk of systemic absorption from a proportionally larger skin surface area relative to body weight, and higher risk of corticosteroid and aminoglycoside-related adverse effects. When used in the diaper area, avoid tight-fitting diapers or plastic pants that cause occlusion.

Elderly

Elderly patients often have thinner skin and may be more prone to skin atrophy and local side effects with corticosteroid-containing products; use the smallest effective amount for the shortest necessary duration.

Renal/hepatic impairment

No formal dose adjustment is established for topical use; systemic absorption is expected to be minimal with correct use, but caution is advised in patients with significant renal impairment if used over large areas or for prolonged periods, due to potential neomycin absorption.

Tetracomb should be used for the shortest duration necessary to control the condition, typically guided by the prescribing physician and reassessed if no improvement is seen within 1-2 weeks. Continuous use beyond the period advised by the physician is not recommended due to increasing risk of skin atrophy, sensitization (especially to neomycin), and microbial resistance.

Triamcinolone + Neomycin + Nystatin + Gramicidin is classified as a topical corticosteroid + antibacterial (aminoglycoside and polypeptide) + antifungal (polyene) combination product.

Triamcinolone + Neomycin + Nystatin + Gramicidin acts through four complementary mechanisms: triamcinolone acetonide suppresses local inflammatory and immune mediator release via glucocorticoid receptor activation; neomycin sulphate and gramicidin inhibit bacterial protein synthesis and disrupt bacterial cell membrane integrity respectively, together covering common gram-positive and gram-negative skin pathogens; and nystatin binds ergosterol in the fungal cell membrane of Candida species, causing pore formation, leakage of cell contents, and fungal cell death. Together, these actions reduce inflammation, itching, and both bacterial and candidal infection at the application site.

Tetracomb may be used in children under medical supervision for infected inflammatory skin conditions such as infected eczema, intertrigo, and infected diaper dermatitis. It is generally not recommended for infants under 1 year of age because of the increased risk of systemic absorption of the corticosteroid and neomycin components through a proportionally larger skin surface area. Safety and efficacy of long-term or repeated use in children have not been established, and treatment should be limited to the shortest effective duration under a physician's guidance. Avoid occlusive diapering or dressings during treatment in infants.